Capricor Therapeutics, Inc. (CAPR) stock
CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.41+0.11 (+1.33%)
Close on Nov 17, 2026Market cap $488.95MP/E –Yield –
Capricor Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Capricor Therapeutics's price to sales ratio was 26.0× on Apr 30, 2025, against 6.5× a year earlier. Over the last 5 years it ranged from 3.7× to 407.2×, with a median of 24.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Apr 30, 2025 | 26.0× | +2.0 |
| 2024 | Dec 31, 2024 | 24.0× | +15.0 |
| 2023 | Dec 29, 2023 | 9.0× | −304.1 |
| 2022 | Apr 29, 2022 | 313.1× | +79.3 |
| 2021 | Dec 31, 2021 | 233.7× | +87.6 |
| 2020 | Dec 31, 2020 | 146.1× | +142.4 |
| 2019 | Dec 31, 2019 | 3.7× | −4.7 |
| 2018 | Dec 31, 2018 | 8.4× | −4.4 |
| 2017 | Dec 29, 2017 | 12.8× | −0.7 |
| 2016 | Dec 30, 2016 | 13.5× | +4.9 |
| 2015 | Dec 31, 2015 | 8.6× | −4.4 |
| 2014 | Dec 31, 2014 | 13.0× | −53.2 |
| 2013 | Dec 31, 2013 | 66.1× | +1.3 |
| 2012 | Dec 31, 2012 | 64.8× | – |
See a number that looks wrong?